Validating ddPCR for Gene Therapy Biodistribution in Minipigs: A New Industry Benchmark
As gene therapy programs advance toward IND-enabling studies, robust biodistribution data are more critical than ever. But while regulatory expectations for vector biodistribution are clear, detailed guidance on validating droplet digital PCR (ddPCR) assays, particularly in large animal models, remains limited.
In a published study in The AAPS Journal, scientists from Smithers Pharmaceutical Development Services describe the development and full validation of a duplex ddPCR assay to quantify AVGN7, an AAV-based gene therapy, in Göttingen minipig tissues.
The study establishes:
• Sensitivity down to 10 copies/µg gDNA
• Strong intra- and inter-assay accuracy and precision
• Demonstrated ruggedness across analysts, instruments, and reagent lots
• Optimized DNA extraction methods for challenging tissues
• A regulatory-aligned validation framework suitable for GLP studies
Importantly, this work provides one of the first validated ddPCR biodistribution assays in minipigs, an increasingly preferred large animal model for gene therapy development.
For sponsors navigating preclinical gene therapy programs, this publication offers both practical validation guidance and a procedural roadmap for future assays.
Download the full white paper to explore the methodology, validation criteria, and regulatory considerations in detail.
